Parkman Healthcare Partners LLC Raises Holdings in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• Parkman Healthcare Partners LLC increased its holdings in Maravai LifeSciences by 88.6% in Q1 2023, owning approximately 0.26% of the company, which is valued at about $1.46 million.
• Several hedge funds, including PenderFund Capital Management and Jacobs Levy Equity Management, also boosted their positions in Maravai, indicating a growing institutional interest.
• Equities research analysts have adjusted their price targets for Maravai LifeSciences, with a consensus target price of $5.22 and ratings ranging from Buy to Sell.

Parkman Healthcare Partners LLC boosted its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 88.6% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 660,000 shares of the company's stock after acquiring an additional 310,000 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.26% of Maravai LifeSciences worth $1,459,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of MRVI. EntryPoint Capital LLC purchased a new stake in Maravai LifeSciences in the first quarter valued at approximately $32,000. Teacher Retirement System of Texas purchased a new stake in Maravai LifeSciences in the first quarter valued at $37,000. Aigen Investment Management LP purchased a new position in shares of Maravai LifeSciences during the 1st quarter valued at about $37,000. Performa Ltd US LLC raised its position in Maravai LifeSciences by 245.0% during the first quarter. Performa Ltd US LLC now owns 17,250 shares of the company's stock valued at $38,000 after acquiring an additional 12,250 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. acquired a new stake in shares of Maravai LifeSciences during the 1st quarter worth approximately $55,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Price Performance

NASDAQ:MRVI traded up $0.19 during trading hours on Thursday, reaching $2.79. 981,588 shares of the company were exchanged, compared to its average volume of 2,292,276. The company has a current ratio of 5.16, a quick ratio of 4.49 and a debt-to-equity ratio of 0.68. The firm has a market cap of $712.45 million, a PE ratio of -2.05 and a beta of 0.29. Maravai LifeSciences Holdings, Inc. has a twelve month low of $1.66 and a twelve month high of $9.50. The stock's 50-day moving average is $2.49 and its 200-day moving average is $2.35.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada cut their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a report on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Maravai LifeSciences has a consensus rating of "Hold" and a consensus price target of $5.22.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.